| Date | Form | Description | Docs | XBRL | Pages |
| 07/28/99 | 8-K | Current report filing |
|
10 | |
| 06/28/99 | DEF 14A | Definitive proxy statements |
|
9 | |
| 06/17/99 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
6 | |
| 06/14/99 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
25 | |
| 03/31/99 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
13 | |
| 03/16/99 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
16 | |
| 01/29/99 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
42 | |
| 09/14/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
15 | |
| 06/29/98 | DEF 14A | Definitive proxy statements |
|
9 | |
| 06/15/98 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...